Observing gut health in children with leukemia
Monitor Gut Health in Children Undergoing Treatment for Acute Myeloid Leukaemia Treatment: Case-control Study
This study looks at how leukemia treatment affects gut health and recovery in children aged 0-16 to see if nutrition plays a role in their healing process.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 1 Month to 16 Years |
| Sex | All |
| Sponsor | Great Ormond Street Hospital for Children NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT06899581 on ClinicalTrials.gov |
What this trial studies
This study aims to observe how leukemia treatment affects gut health, specifically the microbiome, and how quickly recovery occurs post-treatment. It will monitor the nutritional status and gut health of children aged 0-16 undergoing treatment for acute myelogenous leukemia (AML), hemophagocytic lymphohistiocytosis (HLH), or Burkitt lymphoma/leukemia. Measurements will be taken during routine medical appointments at Great Ormond Street Hospital, focusing on the impact of nutrition and feeding on gut recovery. The study seeks to understand the relationship between chemotherapy-induced intestinal mucositis and overall recovery.
Who should consider this trial
Good fit: Ideal candidates are children aged 0-16 diagnosed with AML, HLH, or Burkitt lymphoma/leukemia.
Not a fit: Patients over 16 years old or those with inflammatory bowel diseases like ulcerative colitis or Crohn's disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved nutritional strategies that enhance recovery and overall health in children undergoing leukemia treatment.
How similar studies have performed: While studies on gut health in cancer patients exist, this specific observational approach focusing on pediatric leukemia and its nutritional implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Consented to partake in the study * Aged 0-16 years old * Diagnosed with AML/HLH/ Burkits Exclusion Criteria: * 17 years old + (treated at UCL adolescent unit) * Inflammatory bowel disease: ulcerative colitis or Crohn's disease * Children who had previously been treated with chemotherapy in another institution age
Where this trial is running
London
- Great Ormond Street Hospital — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Graeme O'Connor, PhD
- Email: graeme.oconnor@nhs.net
- Phone: +4474059200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.